News from the ECOG-ACRIN Cancer Research Group
July 7, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, June/July 2021

ECOG-ACRIN will hold its Fall 2021 Group Meeting as a face-to-face meeting for the first time in two years
July 7, 2021
Woman on smartphone

Mi Guía (My Guide) App for Hispanic/Latina Patients with Breast Cancer

Could a culturally-sensitive app help improve endocrine therapy medication adherence in Hispanic/Latina patients undergoing breast cancer treatment?
July 7, 2021
Barbara Burtness, MD

ECOG-ACRIN Creates Task Force on Advancement for Women

ECOG-ACRIN has established a Task Force on Advancement for Women under the leadership of Barbara Burtness, MD of Yale University
July 7, 2021
TMIST recruitment graph

Trial Updates: TMIST Enrollment Hits 50,000; NCI-MATCH News; Recent Research Results

Recent ECOG-ACRIN trial updates and results
July 7, 2021
Doctor patient consult in office

Now Enrolling: EA8192 for Upper Urinary Tract Cancer

This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
July 7, 2021
Colorectal cancer awareness ribbon

Now Enrolling: EA2201 for Rectal Adenocarcinoma

This phase II study will test the effect of nivolumab plus ipilimumab, with short-course radiation, for the neoadjuvant treatment of patients with low-lying, locally advanced MSI-H/dMMR rectal cancer
July 7, 2021
Older woman walking with doctor

Trial Spotlight: Efrat Dotan on the GIANT Study for Older Adults with Pancreatic Cancer

The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
July 7, 2021
News in Brief

News in Brief, June 2021